PYXS Latest Press Releases

-- October 27, 2026 --

Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Globe Newswire 8:45 AM

-- October 2, 2026 --

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering Globe Newswire 7:00 AM

-- September 30, 2026 --

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering Globe Newswire 1:11 AM

-- September 29, 2026 --

Pyxis Oncology Announces Proposed Public Offering Globe Newswire 4:24 PM

-- September 9, 2026 --

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) Globe Newswire 7:00 AM

-- September 8, 2026 --

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) Globe Newswire 4:01 PM

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board Globe Newswire 7:30 AM

-- September 1, 2026 --

Pyxis Oncology to Participate in Upcoming Investor Conferences Globe Newswire 7:30 AM

-- August 13, 2026 --

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Globe Newswire 7:00 AM

-- June 30, 2026 --

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes